A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of A High-Fat Meal on the Pharmacokinetics of Bexagliflozin in Healthy Subjects
Latest Information Update: 31 May 2021
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Theracos
- 26 Sep 2016 Status changed from recruiting to completed.
- 21 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
- 13 Jul 2016 New trial record